Developing CEST-detectable liposomal hydrogel for monitoring local brain tumor treatment

Glioblastoma is a malignant form of brain tumors, which has a high recurrence even with combined treatments. Here, we developed anti-cancer drugs loaded liposomal hydrogels for a sustainable drug release to treat brain tumors locally under MRI guidance. These anti-cancer drugs are CEST-detectable. We observed a continuous decrease in tumor size and CEST contrast at 3.5 and -3.5 ppm compared to control group, where drug-free liposomal hydrogel was injected. The therapeutic efficacy of local drug delivery using liposomal hydrogel was evidenced and can be monitored using CEST multiple-contrast approach. This could serve a robust theranostic application for local brain tumor treatment.